Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Series E Warrants [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Re-priced Warrants [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Warrants Issued to CEO [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Expense Warrant for Note Extension [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Warrant for Promissory Notes [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Warrants Issued to Helomics' Investors [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Warrants Held by Noteholders [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Private Placement [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Over-Allotment Option [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Chief Executive Officer [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Bridge Notes [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Helomics Acquisition, Inc. [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Consulting Agreement One [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Contract with TumorGenesis [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] TumorGenesis [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Warrants Issued to CEO [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Expense Warrant for Note Extension [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Warrant for Promissory Notes [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Warrants Issued to Helomics' Investors [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Warrants Held by Noteholders [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Private Placement [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Chief Executive Officer [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Bridge Notes [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member]	Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Warrants Issued to CEO [Member]	Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Expense Warrant for Note Extension [Member]	Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Warrant for Promissory Notes [Member]	Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Warrants Issued to Helomics' Investors [Member]	Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Warrants Held by Noteholders [Member]	Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Private Placement [Member]	Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Chief Executive Officer [Member]	Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Bridge Notes [Member]	Preferred Stock [Member] Series E Convertible Preferred Stock [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Series E Warrants [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Re-priced Warrants [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Private Placement [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Over-Allotment Option [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Bridge Notes [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Helomics Acquisition, Inc. [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member] TumorGenesis [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member]	Common Stock [Member] Series E Warrants [Member]	Common Stock [Member] Re-priced Warrants [Member]	Common Stock [Member] Warrants Issued to CEO [Member]	Common Stock [Member] Expense Warrant for Note Extension [Member]	Common Stock [Member] Warrant for Promissory Notes [Member]	Common Stock [Member] Warrants Issued to Helomics' Investors [Member]	Common Stock [Member] Warrants Held by Noteholders [Member]	Common Stock [Member] Private Placement [Member]	Common Stock [Member] Over-Allotment Option [Member]	Common Stock [Member] Chief Executive Officer [Member]	Common Stock [Member] Bridge Notes [Member]	Common Stock [Member] Helomics Acquisition, Inc. [Member]	Common Stock [Member] Consulting Agreement One [Member]	Common Stock [Member] Contract with TumorGenesis [Member]	Common Stock [Member] TumorGenesis [Member]	Common Stock [Member]	Additional Paid-in Capital [Member] Series E Warrants [Member]	Additional Paid-in Capital [Member] Re-priced Warrants [Member]	Additional Paid-in Capital [Member] Warrants Issued to CEO [Member]	Additional Paid-in Capital [Member] Expense Warrant for Note Extension [Member]	Additional Paid-in Capital [Member] Warrant for Promissory Notes [Member]	Additional Paid-in Capital [Member] Warrants Issued to Helomics' Investors [Member]	Additional Paid-in Capital [Member] Warrants Held by Noteholders [Member]	Additional Paid-in Capital [Member] Private Placement [Member]	Additional Paid-in Capital [Member] Over-Allotment Option [Member]	Additional Paid-in Capital [Member] Chief Executive Officer [Member]	Additional Paid-in Capital [Member] Bridge Notes [Member]	Additional Paid-in Capital [Member] Helomics Acquisition, Inc. [Member]	Additional Paid-in Capital [Member] Consulting Agreement One [Member]	Additional Paid-in Capital [Member] Contract with TumorGenesis [Member]	Additional Paid-in Capital [Member] TumorGenesis [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member] Series E Warrants [Member]	Retained Earnings [Member] Re-priced Warrants [Member]	Retained Earnings [Member] Warrants Issued to CEO [Member]	Retained Earnings [Member] Expense Warrant for Note Extension [Member]	Retained Earnings [Member] Warrant for Promissory Notes [Member]	Retained Earnings [Member] Warrants Issued to Helomics' Investors [Member]	Retained Earnings [Member] Warrants Held by Noteholders [Member]	Retained Earnings [Member] Private Placement [Member]	Retained Earnings [Member] Over-Allotment Option [Member]	Retained Earnings [Member] Chief Executive Officer [Member]	Retained Earnings [Member] Bridge Notes [Member]	Retained Earnings [Member] Helomics Acquisition, Inc. [Member]	Retained Earnings [Member] Consulting Agreement One [Member]	Retained Earnings [Member] Contract with TumorGenesis [Member]	Retained Earnings [Member] TumorGenesis [Member]	Retained Earnings [Member]	Series E Convertible Preferred Stock [Member]	Series E Warrants [Member]	Re-priced Warrants [Member]	Warrants Issued to CEO [Member]	Expense Warrant for Note Extension [Member]	Warrant for Promissory Notes [Member]	Warrants Issued to Helomics' Investors [Member]	Warrants Held by Noteholders [Member]	Private Placement [Member]	Over-Allotment Option [Member]	Chief Executive Officer [Member]	Bridge Notes [Member]	Helomics Acquisition, Inc. [Member]	Consulting Agreement One [Member]	Contract with TumorGenesis [Member]	TumorGenesis [Member]	Total
Balance (in shares) at Dec. 31, 2017																79,246																										647,819																694,328
Balance at Dec. 31, 2017																$ 792																										$ 6,479																$ 6,943																$ 57,442,745																$ (54,765,045)																	$ 2,691,914
Warrant exercises (in shares)																																											14,539	50,467
Warrant exercises																																											$ 145	$ 505															$ 145,251	$ 504,160																																$ 145,396	$ 504,665
Shares issued for services (in shares)																																																										25,000
Shares issued for services																																																										$ 250																294,750																																	295,000
Shares issued in escrow pursuant to a contract with TumorGenesis at $11.70 per share (in shares)																																																									75,000
Shares issued in escrow pursuant to a contract with TumorGenesis at $11.70 per share																																																									$ 750																$ 876,750																																	$ 877,500
Stock issuable for bridge loan																																																																					$ 206,605																																	$ 206,605
Warrants issued per bridge loan																																																																										143,707																																	143,707
Vesting Expense																																																																										800,322																																	800,322
Net loss																																																																																										(6,640,301)																	(6,640,301)
Preferred conversion to common shares pursuant to private placement agreement (in shares)																																					(647,819)													58,975
Preferred conversion to common shares pursuant to private placement agreement																																					$ (6,479)													$ 590																$ 5,889																																									(6,479)
Shares issued (in shares)																																																			21,525							290,000
Shares issued																																																			$ 215							$ 2,900									$ 204,206							2,752,187																										$ 204,422							2,755,087
Shares issued for acquisition (in shares)																																																						110,000
Shares issued for acquisition																																																						$ 1,100																$ 1,041,150																																	$ 1,042,250
Shares issued																																																																																			$ 1
Balance (in shares) at Sep. 30, 2018																79,246																																										1,339,834
Balance at Sep. 30, 2018																$ 792																																										$ 13,398																64,417,722																(61,405,345)																	3,026,567
Balance (in shares) at Jun. 30, 2018																79,246																																										1,208,945
Balance at Jun. 30, 2018																$ 792																																										$ 12,089																62,247,373																(58,898,476)																	3,361,778
Warrant exercises (in shares)																																											5,656	25,233
Warrant exercises																																											$ 57	$ 252															$ 56,503	$ 252,080																																$ 56,560	$ 252,332
Shares issued for services (in shares)																																																							25,000
Shares issued for services																																																							$ 250																$ 294,750																																	$ 295,000
Shares issued in escrow pursuant to a contract with TumorGenesis at $11.70 per share (in shares)																																																								75,000
Shares issued in escrow pursuant to a contract with TumorGenesis at $11.70 per share																																																								$ 750																$ 876,750																																	$ 877,500
Stock issuable for bridge loan																																																																										206,605																																	206,605
Warrants issued per bridge loan																																																																										143,707																																	143,707
Vesting Expense																																																																										339,954																																	339,954
Net loss																																																																																										(2,506,869)																	(2,506,869)
Balance (in shares) at Sep. 30, 2018																79,246																																										1,339,834
Balance at Sep. 30, 2018																$ 792																																										$ 13,398																64,417,722																(61,405,345)																	3,026,567
Balance (in shares) at Dec. 31, 2018																79,246																																										1,409,175
Balance at Dec. 31, 2018																$ 792																																										$ 14,092																63,146,533																(63,107,945)																	53,472
Warrant exercises (in shares)																																																										59,700
Warrant exercises																																																										$ 597																5,373																																	5,970
Warrants issued per bridge loan																																																													$ 356,471		$ 180,640	$ 6,261,590	$ 177,343																													$ 356,471		$ 180,640	$ 6,261,590	$ 177,343
Vesting Expense																																																																										2,004,366																																	2,004,366
Net loss																																																																																										(5,836,592)																	(5,836,592)
Shares issued pursuant to debt (in shares)																																																					23,857					82,432
Shares issued pursuant to debt																																																					$ 239					$ 824											119,135					337,749																												119,374					338,573
Issuance of Series E Preferred shares (in shares)																																		257.7																																																									257.7
Issuance of Series E Preferred shares																																		$ 3																																								2,338,837																																	2,338,840
Preferred conversion to common shares pursuant to private placement agreement
Shares issued (in shares)																																																		286,375		7,813
Shares issued																																																		$ 2,864		$ 78														$ 2,426,844		$ 49,922																							$ 2,577,000								$ 2,429,708		$ 50,000
Shares issued for acquisition (in shares)																									3,500,000																																	400,000
Shares issued for acquisition																									$ 35,000																																	$ 4,000																5,573,250																																	5,612,250
Shares issued in forbearance agreement (in shares)																																																										16,667
Shares issued in forbearance agreement																																																										$ 166																158,183																																	158,349
Stock issued to extinguish debt as part of Helomics purchase consideration (in shares)																																																										863,732
Value of shares to extinguish debt (iii)																																																										$ 8,637																6,454,672																																	6,463,309
Balance (in shares) at Sep. 30, 2019																79,246									3,500,000									257.7																								3,149,751
Balance at Sep. 30, 2019																$ 792									$ 35,000									$ 3																								$ 31,497																89,590,908																(68,944,537)																	20,713,663
Balance (in shares) at Jun. 30, 2019																79,246									3,500,000									84.3																								3,097,476
Balance at Jun. 30, 2019																$ 792									$ 35,000									$ 1																								$ 30,975																87,160,845																(64,936,025)																	22,291,588
Warrant exercises (in shares)																																																										1,844
Warrant exercises																																																										$ 18																166																																	184
Warrants issued per bridge loan																																																													$ 14,863	$ 60,100	$ 180,640																															$ 14,863	$ 60,100	$ 180,640
Vesting Expense																																																																										360,146																																	360,146
Net loss																																																																																										(4,008,512)																	(4,008,512)
Shares issued pursuant to debt (in shares)																																																					23,858					26,573
Shares issued pursuant to debt																																																					$ 238					$ 266											$ 119,136					99,734																												$ 119,374					100,000
Issuance of Series E Preferred shares (in shares)																																		173.4																																																									173.4
Issuance of Series E Preferred shares																																		$ 2																																								1,595,278																																	1,595,280
Balance (in shares) at Sep. 30, 2019																79,246									3,500,000									257.7																								3,149,751
Balance at Sep. 30, 2019																$ 792									$ 35,000									$ 3																								$ 31,497																$ 89,590,908																$ (68,944,537)																	$ 20,713,663